Posted by Michael Wonder on 27 Aug 2020
The EU Commission grants conditional approval for Idefirix (imlifidase) in highly sensitised kidney transplant patients in the European Union
26 August 2020 - The conditional approval by the European Commission serves as a landmark milestone for Hansa Biopharma, as Idefirix (imlifidase) will be the Company’s first approved drug and will transform Hansa Biopharma into a commercial stage biopharmaceutical company.
Hansa Biopharma today announced that the European Commission has granted conditional approval for Idefirix in highly sensitised kidney transplants patients.
